TY - JOUR
T1 - CA 72-4 serum marker-a new tool in the management of carcinoma patients
AU - Guadagni, Fiorella
AU - Roselli, Mario
AU - Cosimelli, Maurizio
AU - Ferroni, Patrizia
AU - Spila, Antonella
AU - Cavaliere, Francesco
AU - Casaldi, Valerio
AU - Wappner, Giulia
AU - Abbolito, Maria Rosaria
AU - Greiner, John W.
AU - Schlom, Jeffrey
PY - 1995
Y1 - 1995
N2 - Among the new tumor markers that have been recently proposed, CA 72-4 is of particular interest, not only for its capabilities in diagnosing and monitoring certain neoplastic diseases, but also for its excellent specificity. Several studies focused on the potential clinical usefulness ofCA 72-4 in gastrointestinal (GI) and gynecological cancer, showing a sensitivity of approximately 40% in colorectal and gastric cancer and 50% in ovarian cancer, with an overall specificity of more than 95% Longitudinal evaluations of patients with either GI or gynecological malignant diseases demonstrated that significant elevations of CA 72-4 serum levels may be predictive of recurrent disease. Moreover, the combination of CA 72-4 with other known serum markers, such as CEA and CA 19-9 for GI cancer or CA 125 for ovarian cancer, indicated that an increase in the sensitivity can be achieved without substantial changes in the overall specificity, improving the possibility of monitoring these patients. In conclusion, these results provide a strong argument for the use of CA 72-4 in the management of these neoplastic diseases.
AB - Among the new tumor markers that have been recently proposed, CA 72-4 is of particular interest, not only for its capabilities in diagnosing and monitoring certain neoplastic diseases, but also for its excellent specificity. Several studies focused on the potential clinical usefulness ofCA 72-4 in gastrointestinal (GI) and gynecological cancer, showing a sensitivity of approximately 40% in colorectal and gastric cancer and 50% in ovarian cancer, with an overall specificity of more than 95% Longitudinal evaluations of patients with either GI or gynecological malignant diseases demonstrated that significant elevations of CA 72-4 serum levels may be predictive of recurrent disease. Moreover, the combination of CA 72-4 with other known serum markers, such as CEA and CA 19-9 for GI cancer or CA 125 for ovarian cancer, indicated that an increase in the sensitivity can be achieved without substantial changes in the overall specificity, improving the possibility of monitoring these patients. In conclusion, these results provide a strong argument for the use of CA 72-4 in the management of these neoplastic diseases.
UR - http://www.scopus.com/inward/record.url?scp=0028912845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028912845&partnerID=8YFLogxK
U2 - 10.3109/07357909509011692
DO - 10.3109/07357909509011692
M3 - Article
C2 - 7874576
AN - SCOPUS:0028912845
VL - 13
SP - 227
EP - 238
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 2
ER -